nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.12.2008

Tumor detection using folate receptor-targeted imaging agents

verfasst von: Emanuela I. Sega, Philip S. Low

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Folate receptors are up-regulated on a variety of human cancers, including cancers of the breast, ovaries, endometrium, lungs, kidneys, colon, brain, and myeloid cells of hematopoietic origin. This over-expression of folate receptors (FR) on cancer tissues can be exploited to target folate-linked imaging and therapeutic agents specifically to FR-expressing tumors, thereby avoiding uptake by most healthy tissues that express few if any FR. Four folate-targeted therapeutic drugs are currently undergoing clinical trials, and several folate-linked chemotherapeutic agents are in late stage preclinical development. However, because not all cancers express FR, and because only FR-expressing cancers respond to FR-targeted therapies, FR-targeted imaging agents have been required to select patients with FR-expressing tumors likely to respond to folate-targeted therapies. This review focuses on recent advances in the use of the vitamin folic acid to target PET agents, γ-emitters, MRI contrast agents and fluorescent dyes to FR⁺ cancers for the purpose of diagnosing and imaging malignant masses with improved specificity and sensitivity.

Bettio, A., Honer, M., Muller, C., Bruhlmeier, M., Muller, U., Schibli, R., et al. (2006). Synthesis and preclinical evaluation of a folic acid derivative labeled with ¹⁸F for PET imaging of folate receptor-positive tumors. Journal of Nuclear Medicine, 47, 1153–1160.PubMed

Breeman, W. A., Kwekkeboom, D. J., de Blois, E., de Jong, M., Visser, T. J., & Krenning, E. P. (2007). Radiolabelled regulatory peptides for imaging and therapy. Anticancer Agents in Medicinal Chemistry, 7, 345–357.CrossRef

Gabriel, M., Decristoforo, C., Kendler, D., Dobrozemsky, G., Heute, D., Uprimny, C., et al. (2007). 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. Journal of Nuclear Medicine, 48, 508–518.PubMedCrossRef

Grotzinger, C., & Wiedenmann, B. (2004). Somatostatin receptor targeting for tumor imaging and therapy. Annals of the New York Academy of Sciences, 1014, 258–264.PubMedCrossRef

Breeman, W. A., de Jong, M., Kwekkeboom, D. J., Valkema, R., Bakker, W. H., Kooij, P. P., et al. (2001). Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. European Journal of Nuclear Medicine, 28, 1421–1429.PubMedCrossRef

Smith, C. J., Volkert, W. A., & Hoffman, T. J. (2005). Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nuclear Medicine and Biology, 32, 733–740.PubMedCrossRef

Prasanphanich, A. F., Nanda, P. K., Rold, T. L., Ma, L., Lewis, M. R., Garrison, J. C., et al. (2007). [⁶⁴Cu-NOTA-8-Aoc-BBN(7–14)NH₂] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proceedings of the National Academy of Sciences of the United States of America, 104, 12462–12467.PubMedCrossRef

Zhang, X., Cai, W., Cao, F., Schreibmann, E., Wu, Y., Wu, J. C., et al. (2006). ¹⁸F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. Journal of Nuclear Medicine, 47, 492–501.PubMed

Leuschner, C., Kumar, C. S., Hansel, W., Soboyejo, W., Zhou, J., & Hormes, J. (2006). LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Research and Treatment, 99, 163–176.PubMedCrossRef

10.

Cai, W., Chen, K., He, L., Cao, Q., Koong, A., & Chen, X. (2007). Quantitative PET of EGFR expression in xenograft-bearing mice using ⁶⁴Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. European Journal of Nuclear Medicine and Molecular Imaging, 34, 850–858.PubMedCrossRef

11.

Perik, P. J., Lub-De Hooge, M. N., Gietema, J. A., van der Graaf, W. T., de Korte, M. A., Jonkman, S., et al. (2006). Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Journal of Clinical Oncology, 24, 2276–2282.PubMedCrossRef

12.

Reilly, R. M., Kiarash, R., Sandhu, J., Lee, Y. W., Cameron, R. G., Hendler, A., et al. (2000). A comparison of EGF and MAb 528 labeled with ¹¹¹In for imaging human breast cancer. Journal of Nuclear Medicine, 41, 903–911.PubMed

13.

Nagengast, W. B., de Vries, E. G., Hospers, G. A., Mulder, N. H., de Jong, J. R., Hollema, H., et al. (2007). In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. Journal of Nuclear Medicine, 48, 1313–1319.PubMedCrossRef

14.

Cai, W., & Chen, X. (2007). Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Frontiers in Bioscience, 12, 4267–4279.PubMedCrossRef

15.

Low, P. S., Henne, W. A., & Doorneweerd, D. D. (2008). Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Accounts of Chemical Research, 41(1), 120–129.PubMedCrossRef

16.

Reddy, J. A., Allagadda, V. M., & Leamon, C. P. (2005). Targeting therapeutic and imaging agents to folate receptor positive tumors. Current Pharmaceutical Biotechnology, 6, 131–150.PubMedCrossRef

17.

Hilgenbrink, A. R., & Low, P. S. (2005). Folate receptor-mediated drug targeting: from therapeutics to diagnostics. Journal of Pharmaceutical Sciences, 94, 2135–2146.PubMedCrossRef

18.

Collins, D. A., Hogenkamp, H. P., & Gebhard, M. W. (1999). Tumor imaging via indium 111-labeled DTPA-adenosylcobalamin. Mayo Clinic Proceedings, 74, 687–691.PubMed

19.

Jasanoff, A. (2005). Functional MRI using molecular imaging agents. Trends in Neurosciences, 28, 120–126.PubMedCrossRef

20.

Shen, F., Ross, J. F., Wang, X., & Ratnam, M. (1994). Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry, 33, 1209–1215.PubMedCrossRef

21.

Antony, A. C. (1996). Folate receptors. Annual Review of Nutrition, 16, 501–521.PubMedCrossRef

22.

Coney, L. R., Tomassetti, A., Carayannopoulos, L., Frasca, V., Kamen, B. A., Colnaghi, M. I., et al. (1991). Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Research, 51, 6125–6132.PubMed

23.

Campbell, I. G., Jones, T. A., Foulkes, W. D., & Trowsdale, J. (1991). Folate-binding protein is a marker for ovarian cancer. Cancer Research, 51, 5329–5338.PubMed

24.

Weitman, S. D., Lark, R. H., Coney, L. R., Fort, D. W., Frasca, V., Zurawski Jr., V. R., et al. (1992). Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Research, 52, 3396–3401.PubMed

25.

Ross, J. F., Chaudhuri, P. K., & Ratnam, M. (1994). Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer, 73, 2432–2443.PubMedCrossRef

26.

Mantovani, L. T., Miotti, S., Menard, S., Canevari, S., Raspagliesi, F., Bottini, C., et al. (1994). Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. European Journal of Cancer, 30A, 363–369.PubMedCrossRef

27.

Holm, J., Hansen, S. I., Sondergaard, K., & Hoier-Madsen, M. (1993). Chemistry and biology of pteridines and folates. The high-affinity folate binding protein in normal and malignant mammary gland tissue. New York: Plenum.

28.

Weitman, S. D., Weinberg, A. G., Coney, L. R., Zurawski, V. R., Jennings, D. S., & Kamen, B. A. (1992). Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Research, 52, 6708–6711.PubMed

29.

Holm, J., Hansen, S. I., Hoier-Madsen, M., & Bostad, L. (1991). High-affinity folate binding in human choroid plexus. Characterization of radioligand binding, immunoreactivity, molecular heterogeneity and hydrophobic domain of the binding protein. Biochemical Journal, 280, 267–271.PubMed

30.

Zimmerman, J. (1990). Folic acid transport in organ-cultured mucosa of human intestine. Evidence for distinct carriers. Gastroenterology, 99, 964–972.PubMed

31.

Morshed, K. M., Ross, D. M., & McMartin, K. E. (1997). Folate transport proteins mediate the bidirectional transport of 5-methyltetrahydrofolate in cultured human proximal tubule cells. Journal of Nutrition, 127, 1137–1147.PubMed

32.

Franklin, W. A., Waintrub, M., Edwards, D., Christensen, K., Prendegrast, P., Woods, J., et al. (1994). New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. International Journal of Cancer—Supplement, 8, 89–95.CrossRef

33.

Holm, J., Hansen, S. I., Hoier-Madsen, M., Helkjaer, P. E., & Nichols, C. W. (1997). Folate receptors in malignant and benign tissues of human female genital tract. Bioscience Reports, 17, 415–427.PubMedCrossRef

34.

Toffoli, G., Cernigoi, C., Russo, A., Gallo, A., Bagnoli, M., & Boiocchi, M. (1997). Overexpression of folate binding protein in ovarian cancers. International Journal of Cancer, 74, 193–198.CrossRef

35.

Garin-Chesa, P., Campbell, I., Saigo, P. E., Lewis Jr., J. L., Old, L. J., & Rettig, W. J. (1993). Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. American Journal of Pathology, 142, 557–567.PubMed

36.

Boerman, O. C., van Niekerk, C. C., Makkink, K., Hanselaar, T. G., Kenemans, P., & Poels, L. G. (1991). Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens. International Journal of Gynecological Pathology, 10, 15–25.PubMedCrossRef

37.

Dainty, L. A., Risinger, J. I., Morrison, C., Chandramouli, G. V., Bidus, M. A., Zahn, C., et al. (2007). Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecologic Oncology, 105, 563–570.PubMedCrossRef

38.

Weitman, S. D., Frazier, K. M., & Kamen, B. A. (1994). The folate receptor in central nervous system malignancies of childhood. Journal of Neuro-Oncology, 21, 107–112.PubMedCrossRef

39.

Hartmann, L. C., Keeney, G. L., Lingle, W. L., Christianson, T. J., Varghese, B., Hillman, D., et al. (2007). Folate receptor overexpression is associated with poor outcome in breast cancer. International Journal of Cancer, 121, 938–942.CrossRef

40.

Paulos, C. M., Turk, M. J., Breur, G. J., & Low, P. S. (2004). Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Advanced Drug Delivery Reviews, 56, 1205–1217.PubMedCrossRef

41.

Nakashima-Matsushita, N., Homma, T., Yu, S., Matsuda, T., Sunahara, N., Nakamura, T., et al. (1999). Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis and Rheumatism, 42, 1609–1616.PubMedCrossRef

42.

Ross, J. F., Wang, H., Behm, F. G., Mathew, P., Wu, M., Booth, R., et al. (1999). Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer, 85, 348–357.PubMedCrossRef

43.

Kamen, B. A., & Smith, A. K. (2004). A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Advanced Drug Delivery Reviews, 56, 1085–1097.PubMedCrossRef

44.

Leamon, C. P., & Low, P. S. (1991). Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proceedings of the National Academy of Sciences of the United States of America, 88, 5572–5576.PubMedCrossRef

45.

Turek, J. J., Leamon, C. P., & Low, P. S. (1993). Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. Journal of Cell Science, 106(Pt 1), 423–430.PubMed

46.

Yang, J., Chen, H., Vlahov, I. R., Cheng, J. X., & Low, P. S. (2006). Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proceedings of the National Academy of Sciences of the United States of America, 103, 13872–13877.PubMedCrossRef

47.

Paulos, C. M., Reddy, J. A., Leamon, C. P., Turk, M. J., & Low, P. S. (2004). Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Molecular Pharmacology, 66, 1406–1414.PubMedCrossRef

48.

Leamon, C. P., Parker, M. A., Vlahov, I. R., Xu, L. C., Reddy, J. A., Vetzel, M., et al. (2002). Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical. Bioconjugate Chemistry, 13, 1200–1210.PubMedCrossRef

49.

Vlashi, E., Sturgis, J., & Low, P. S. Real time, non-invasive and quantitative imaging of the accumulation of ligand-targeted drugs into receptor-expressing solid tumors. in press.

50.

Leamon, C. P., & Low, P. S. (2001). Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discovery Today, 6, 44–51.PubMedCrossRef

51.

Leamon, C. P., & Low, P. S. (1992). Cytotoxicity of momordin–folate conjugates in cultured human cells. Journal of Biological Chemistry, 267, 24966–24971.PubMed

52.

Atkinson, S. F., Bettinger, T., Seymour, L. W., Behr, J. P., & Ward, C. M. (2001). Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells. Journal of Biological Chemistry, 276, 27930–27935.PubMedCrossRef

53.

Leamon, C. P., Reddy, J. A., Vlahov, I. R., Westrick, E., Dawson, A., Dorton, R., et al. (2007). Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Molecular Pharmaceutics, 4, 659–667.PubMedCrossRef

54.

Reddy, J. A., Dorton, R., Westrick, E., Dawson, A., Smith, T., Xu, L. C., et al. (2007). Preclinical evaluation of EC145, a folate–vinca alkaloid conjugate. Cancer Research, 67, 4434–4442.PubMedCrossRef

55.

Leamon, C. P., Reddy, J. A., Vlahov, I. R., Vetzel, M., Parker, N., Nicoson, J. S., et al. (2005). Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic. Bioconjugate Chemistry, 16, 803–811.PubMedCrossRef

56.

Henne, W. A., Doorneweerd, D. D., Hilgenbrink, A. R., Kularatne, S. A., & Low, P. S. (2006). Synthesis and activity of a folate peptide camptothecin prodrug. Bioorganic & Medicinal Chemistry Letters, 16, 5350–5355.CrossRef

57.

Reddy, J. A., & Low, P. S. (2000). Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. Journal of Controlled Release, 64, 27–37.PubMedCrossRef

58.

Xu, L., Pirollo, K. F., Tang, W. H., Rait, A., & Chang, E. H. (1999). Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Human Gene Therapy, 10, 2941–2952.PubMedCrossRef

59.

Zhao, X. B., & Lee, R. J. (2004). Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Advanced Drug Delivery Reviews, 56, 1193–1204.PubMedCrossRef

60.

Pan, X. Q., Zheng, X., Shi, G., Wang, H., Ratnam, M., & Lee, R. J. (2002). Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood, 100, 594–602.PubMedCrossRef

61.

Anderson, K. E., Eliot, L. A., Stevenson, B. R., & Rogers, J. A. (2001). Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form. Pharmaceutical Research, 18, 316–322.PubMedCrossRef

62.

Gabizon, A., Shmeeda, H., Horowitz, A. T., & Zalipsky, S. (2004). Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid–PEG conjugates. Advanced Drug Delivery Reviews, 56, 1177–1192.PubMedCrossRef

63.

Roy, E. J., Gawlick, U., Orr, B. A., & Kranz, D. M. (2004). Folate-mediated targeting of T cells to tumors. Advanced Drug Delivery Reviews, 56, 1219–1231.PubMedCrossRef

64.

Lu, Y., Sega, E., Leamon, C. P., & Low, P. S. (2004). Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Advanced Drug Delivery Reviews, 56, 1161–1176.PubMedCrossRef

65.

Lu, Y., & Low, P. S. (2002). Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunology and Immunotherapy, 51, 153–162.PubMedCrossRef

66.

Cho, B. K., Roy, E. J., Patrick, T. A., & Kranz, D. M. (1997). Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells. Bioconjugate Chemistry, 8, 338–346.PubMedCrossRef

67.

Quintana, A., Raczka, E., Piehler, L., Lee, I., Myc, A., Majoros, I., et al. (2002). Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharmaceutical Research, 19, 1310–1316.PubMedCrossRef

68.

Lu, J. Y., Lowe, D. A., Kennedy, M. D., & Low, P. S. (1999). Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. Journal of Drug Targeting, 7, 43–53.PubMed

69.

Low, P. S., & Antony, A. C. (2004). Folate receptor-targeted drugs for cancer and inflammatory diseases. Advanced Drug Delivery Reviews, 56, 1055–1238.PubMedCrossRef

70.

Mathias, C. J., Wang, S., Lee, R. J., Waters, D. J., Low, P. S., & Green, M. A. (1996). Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. Journal of Nuclear Medicine, 37, 1003–1008.PubMed

71.

Mathias, C. J., Wang, S., Waters, D. J., Turek, J. J., Low, P. S., & Green, M. A. (1998). Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. Journal of Nuclear Medicine, 39, 1579–1585.PubMed

72.

Wang, S., Luo, J., Lantrip, D. A., Waters, D. J., Mathias, C. J., Green, M. A., et al. (1997). Design and synthesis of [¹¹¹In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjugate Chemistry, 8, 673–679.PubMedCrossRef

73.

Guo, W., Hinkle, G. H., & Lee, R. J. (1999). ^99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging. Journal of Nuclear Medicine, 40, 1563–1569.PubMed

74.

Ilgan, S., Yang, D. J., Higuchi, T., Zareneyrizi, F., Bayhan, H., Yu, D., et al. (1998). ^99mTc-ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals. Cancer Biotherapy & Radiopharmaceuticals, 13, 427–435.CrossRef

75.

Mathias, C. J., Hubers, D., Low, P. S., & Green, M. A. (2000). Synthesis of [(99m)Tc]DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical. Bioconjugate Chemistry, 11, 253–257.PubMedCrossRef

76.

Trump, D. P., Mathias, C. J., Yang, Z., Low, P. S., Marmion, M., & Green, M. A. (2002). Synthesis and evaluation of ^99mTc(CO)(3)-DTPA-folate as a folate-receptor-targeted radiopharmaceutical. Nuclear Medicine and Biology, 29, 569–573.PubMedCrossRef

77.

Muller, C., Hohn, A., Schubiger, P. A., & Schibli, R. (2006). Preclinical evaluation of novel organometallic ^99mTc-folate and ^99mTc-pteroate radiotracers for folate receptor-positive tumour targeting. European Journal of Nuclear Medicine and Molecular Imaging, 33, 1007–1016.PubMedCrossRef

78.

Muller, C., Schubiger, P. A., & Schibli, R. (2006). In vitro and in vivo targeting of different folate receptor-positive cancer cell lines with a novel ^99mTc-radiofolate tracer. European Journal of Nuclear Medicine and Molecular Imaging, 33, 1162–1170.PubMedCrossRef

79.

Muller, C., Bruhlmeier, M., Schubiger, P. A., & Schibli, R. (2006). Effects of antifolate drugs on the cellular uptake of radiofolates in vitro and in vivo. Journal of Nuclear Medicine, 47, 2057–2064.PubMed

80.

Weber, W. A. (2006). Positron emission tomography as an imaging biomarker. Journal of Clinical Oncology, 24, 3282–3292.PubMedCrossRef

81.

Barentsz, J., Takahashi, S., Oyen, W., Mus, R., De Mulder, P., Reznek, R., et al. (2006). Commonly used imaging techniques for diagnosis and staging. Journal of Clinical Oncology, 24, 3234–3244.PubMedCrossRef

82.

Rosenbaum, S. J., Lind, T., Antoch, G., & Bockisch, A. (2006). False-positive FDG PET uptake—the role of PET/CT. European Radiology, 16, 1054–1065.PubMedCrossRef

83.

Mathias, C. J., Lewis, M. R., Reichert, D. E., Laforest, R., Sharp, T. L., Lewis, J. S., et al. (2003). Preparation of ⁶⁶Ga- and ⁶⁸Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nuclear Medicine and Biology, 30, 725–731.PubMedCrossRef

84.

Schnall, M., & Rosen, M. (2006). Primer on imaging technologies for cancer. Journal of Clinical Oncology, 24, 3225–3233.PubMedCrossRef

85.

Strijkers, G. J., Mulder, W. J., van Tilborg, G. A., & Nicolay, K. (2007). MRI contrast agents: current status and future perspectives. Anti-Cancer Agents in Medicinal Chemistry, 7, 291–305.PubMedCrossRef

86.

Wiener, E. C., Konda, S. D., Wang, S., & Brechbiel, M. (2002). Imaging folate binding protein expression with MRI. Academic Radiology, 9(Suppl 2), S316–S319.PubMedCrossRef

87.

Choi, H., Choi, S. R., Zhou, R., Kung, H. F., & Chen, I. W. (2004). Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Academic Radiology, 11, 996–1004.PubMedCrossRef

88.

Sun, C., Sze, R., & Zhang, M. (2006). Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. Journal of Biomedical Materials Research, 78, 550–557.PubMed

89.

Becker, A., Hessenius, C., Licha, K., Ebert, B., Sukowski, U., Semmler, W., et al. (2001). Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nature Biotechnology, 19, 327–331.PubMedCrossRef

90.

Cai, W., Shin, D. W., Chen, K., Gheysens, O., Cao, Q., Wang, S. X., et al. (2006). Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Letters, 6, 669–676.PubMedCrossRef

91.

Michalet, X., Pinaud, F. F., Bentolila, L. A., Tsay, J. M., Doose, S., Li, J. J., et al. (2005). Quantum dots for live cells, in vivo imaging, and diagnostics. Science, 307, 538–544.PubMedCrossRef

92.

Gibson, A. P., Hebden, J. C., & Arridge, S. R. (2005). Recent advances in diffuse optical imaging. Physics in Medicine & Biology, 50, R1–R43.CrossRef

93.

Kennedy, M. D., Jallad, K. N., Thompson, D. H., Ben-Amotz, D., & Low, P. S. (2003). Optical imaging of metastatic tumors using a folate-targeted fluorescent probe. Journal of Biomedical Optics, 8, 636–641.PubMedCrossRef

94.

Milstein, A. B., Kennedy, M. D., Low, P. S., Bouman, C. A., & Webb, K. J. (2005). Statistical approach for detection and localization of a fluorescing mouse tumor in intralipid. Applied Optics, 44, 2300–2310.PubMedCrossRef

95.

Tung, C. H., Lin, Y., Moon, W. K., & Weissleder, R. (2002). A receptor-targeted near-infrared fluorescence probe for in vivo tumor imaging. ChemBioChem, 3, 784–786.PubMedCrossRef

96.

Moon, W. K., Lin, Y., O’Loughlin, T., Tang, Y., Kim, D. E., Weissleder, R., et al. (2003). Enhanced tumor detection using a folate receptor-targeted near-infrared fluorochrome conjugate. Bioconjugate Chemistry, 14, 539–545.PubMedCrossRef

97.

He, W., Wang, H., Hartmann, L. C., Cheng, J. X., & Low, P. S. (2007). In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proceedings of the National Academy of Sciences of the United States of America, 104, 11760–11765.PubMedCrossRef

98.

Bharali, D. J., Lucey, D. W., Jayakumar, H., Pudavar, H. E., & Prasad, P. N. (2005). Folate-receptor-mediated delivery of InP quantum dots for bioimaging using confocal and two-photon microscopy. Journal of the American Chemical Society, 127, 11364–11371.PubMedCrossRef

99.

Varghese, B., Haase, N., & Low, P. S. (2007). Depletion of folate-receptor-positive macrophages leads to alleviation of symptoms and prolonged survival in two murine models of systemic lupus erythematosus. Molecular Pharmaceutics, 4, 679–685.PubMedCrossRef

Titel: Tumor detection using folate receptor-targeted imaging agents
verfasst von: Emanuela I. Sega
Philip S. Low
Publikationsdatum: 01.12.2008
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 4/2008
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-008-9155-6

Neu im Fachgebiet Onkologie

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Tumor detection using folate receptor-targeted imaging agents

Abstract

Neu im Fachgebiet Onkologie

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2008

Non-invasive assessment of tumor neovasculature: techniques and clinical applications

Molecular imaging of epidermal growth factor receptor expression–activity at the kinase level in tumors with positron emission tomography

Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography

Preface-imaging in cancer

Imaging hemodynamics

Imaging of tumor glucose utilization with positron emission tomography

Neu im Fachgebiet Onkologie

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Update Onkologie